AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
AIM ImmunoTech Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 39.89M shares outstanding
USAIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States.
Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Leadership
Thomas K. Equels
Executive Vice Chairman, Chief Executive Officer & President
Peter W. Rodino
Chief Operating Officer, Executive Director of Governmental Relations, General Counsel & Secretary
Robert Dickey
Chief Financial Officer
Ann Marie E. Coverly
Director of Administration & Human Resources and Deputy Investor Relations Coordinator
Employees
21
Country
US
Sector
Healthcare
Website
aimimmuno.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Equels Thomas K | CEO & President | Purchase | 31.7K | $5.1K | Oct 23, 2026 |
| Equels Thomas K | CEO & President | Purchase | 31.3K | $5.1K | Oct 22, 2026 |
| Equels Thomas K | CEO & President | Purchase | 24.0K | $5.0K | Sep 17, 2026 |
| Equels Thomas K | CEO & President | Purchase | 11.0K | $2.3K | Sep 16, 2026 |
| Equels Thomas K | CEO & President | Purchase | 22.0K | $4.9K | Sep 15, 2026 |
| Equels Thomas K | CEO & President | Purchase | 5.9K | $1.3K | Sep 14, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Armistice Capital, LLC · may incl. warrants· filed Feb 2025 | 3.4M | 5.0% as filed | 13G |
 KELLNER TED D Director | 2.0M | 4.9% | FORM 4 |
Todd Deutsch · may incl. warrants· filed Dec 2024 | 1.7M | 2.7% as filed | 13D |
JANE STREET GROUP, LLC | 807.9K | 2.0% | 13F |
 MITCHELL WILLIAM M Director | 522.2K | 1.3% | FORM 4 |
 Rodino Peter W III COO, Secretary, Gen. Counsel | 402.2K | 1.0% | FORM 4 |
 APPELROUTH STEWART Director | 389.1K | 1.0% | FORM 4 |
 BRYAN NANCY Director | 292.2K | 0.7% | FORM 4 |
 Equels Thomas K CEO & President, Director | 189.7K | 0.5% | FORM 4 |
Virtu Financial LLC | 124.3K | 0.3% | 13F |
Insiders
- Equels Thomas KCEO & President
- CHEMEROW DAVID I.Director
- KELLNER TED DDirector
- MITCHELL WILLIAM MDirector
- Rodino Peter W IIICOO, Secretary, Gen. Counsel
- BRYAN NANCYDirector
- APPELROUTH STEWARTDirector
based on 39.89M shares outstanding
US30d Avg
759.99K
60d Avg
6.55M
90d Avg
4.77M